Pfizer has announced that it will begin clinical trials of its oral antiviral drug for Covid-19. According to the company, the new candidate drug shows very strong in vitro antiviral activity.
While the coronavirus pandemic that affects the whole world continues, various companies and companies continue their drug development efforts without slowing down. Now the world-renowned Pfizer company has announced that it will begin clinical trials of the oral antiviral drug it developed for Covid-19 in the United States.
According to the company, the new candidate drug shows very strong in vitro – antiviral activity in the laboratory environment – and therefore suggests that the candidate drug could be potentially effective.
It should be noted that the candidate drug, which is in the class of protease inhibitors (some of the Hepatitis B and HIV drugs are also in this class), acts by blocking the enzyme that is very critical in the replication of the virus.
You May Be Interested According to researches, Kovid vaccines reduce deaths by 85% and hospitalizations by 80%.
The company officials emphasized that the pandemic should be addressed in every aspect and that the pandemic should be managed thanks to the use of both vaccines and therapeutic drugs, because it is very important to apply effective treatment methods in sporadic cases that can be seen even if the pandemic ends.
Let’s add that currently the only antiviral drug approved by the FDA, namely the American Food and Drug Administration, is “Remdesivir” owned by the company called Gilead Sciences. The FDA had approved emergency use for several antibody treatments (owned by Regeneron Pharmaceuticals and Eli Lilly and Company).
Finally, it should be noted that the new drug is a candidate to be the first drug to be prescribed to patients with symptoms of Kovid-19 infection, and at the same time, Pfizer has tested various protease inhibitors intravenously on patients hospitalized due to Kovid-19.